Total Payments
$16,431
2024 Payments
$2,611
Companies
62
Transactions
923
Medicare Patients
2,791
Medicare Billing
$311,924
Payment Breakdown by Category
Food & Beverage$16,160 (98.3%)
Education$253.71 (1.5%)
Other$17.77 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $16,160 | 915 | 98.3% |
| Education | $253.71 | 7 | 1.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17.77 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $4,428 | 204 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $1,372 | 85 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $875.92 | 60 | $0 (2024) |
| UCB, Inc. | $834.37 | 36 | $0 (2024) |
| EMD Serono, Inc. | $762.02 | 52 | $0 (2024) |
| Allergan, Inc. | $614.69 | 47 | $0 (2022) |
| Biogen, Inc. | $437.43 | 30 | $0 (2024) |
| Supernus Pharmaceuticals, Inc. | $383.57 | 44 | $0 (2021) |
| Sunovion Pharmaceuticals Inc. | $371.20 | 23 | $0 (2022) |
| GENZYME CORPORATION | $357.65 | 20 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,611 | 134 | ABBVIE INC. ($991.31) |
| 2023 | $2,444 | 122 | ABBVIE INC. ($937.87) |
| 2022 | $2,014 | 94 | ABBVIE INC. ($844.81) |
| 2021 | $3,280 | 153 | AbbVie Inc. ($1,581) |
| 2020 | $1,762 | 115 | Allergan, Inc. ($398.25) |
| 2019 | $1,651 | 137 | Novartis Pharmaceuticals Corporation ($237.99) |
| 2018 | $1,376 | 83 | UCB, Inc. ($222.45) |
| 2017 | $1,292 | 85 | Teva Pharmaceuticals USA, Inc. ($434.76) |
All Payment Transactions
923 individual payment records from CMS Open Payments — Page 1 of 37
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | LivaNova USA, Inc. | VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: Neurology | ||||||
| 12/12/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $17.60 | General |
| 12/12/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $1.42 | General |
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $26.31 | General |
| Category: Neurology | ||||||
| 12/06/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $8.85 | General |
| Category: NEUROSCIENCE | ||||||
| 12/03/2024 | MDD US Operations, LLC | Gocovri (Drug) | Food and Beverage | In-kind items and services | $30.52 | General |
| Category: AMANTADINE | ||||||
| 11/27/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $17.76 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/26/2024 | Abbott Laboratories | INFINITY (Device) | Food and Beverage | In-kind items and services | $19.34 | General |
| Category: Neuromodulation | ||||||
| 11/25/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $30.60 | General |
| Category: Rare Disease | ||||||
| 11/22/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $12.28 | General |
| Category: NEUROSCIENCE | ||||||
| 11/21/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $22.14 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $11.26 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/15/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $13.86 | General |
| Category: NEUROSCIENCE | ||||||
| 11/13/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $22.93 | General |
| 11/11/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Food and Beverage | In-kind items and services | $14.32 | General |
| Category: Adenosine A2A Receptors | ||||||
| 11/08/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $17.23 | General |
| Category: NEUROSCIENCE | ||||||
| 11/06/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $25.49 | General |
| Category: NEUROSCIENCE | ||||||
| 11/04/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $23.34 | General |
| Category: Rare Disease | ||||||
| 11/04/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: Central Nervous System | ||||||
| 11/01/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $13.18 | General |
| Category: NEUROSCIENCE | ||||||
| 10/29/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 10/29/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $2.41 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 10/28/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $25.76 | General |
| Category: Neurology | ||||||
| 10/25/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: NEUROSCIENCE | ||||||
| 10/18/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $12.69 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 606 | 760 | $211,811 | $66,401 |
| 2022 | 9 | 645 | 821 | $229,369 | $73,718 |
| 2021 | 10 | 770 | 955 | $281,877 | $91,469 |
| 2020 | 9 | 770 | 937 | $281,675 | $80,335 |
Total Patients
2,791
Total Services
3,473
Medicare Billing
$311,924
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 219 | 295 | $52,510 | $18,546 | 35.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 108 | 129 | $33,927 | $12,075 | 35.6% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 83 | 133 | $29,925 | $9,669 | 32.3% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 58 | 63 | $36,792 | $8,506 | 23.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 63 | 63 | $25,200 | $7,651 | 30.4% |
| 95813 | Measurement of brain wave activity (eeg), 61-119 minutes | Office | 2023 | 17 | 17 | $16,932 | $5,427 | 32.1% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 17 | 17 | $8,313 | $2,058 | 24.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 17 | 17 | $4,471 | $1,395 | 31.2% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 24 | 26 | $3,741 | $1,075 | 28.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 227 | 320 | $56,960 | $19,866 | 34.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 125 | 156 | $41,028 | $13,642 | 33.2% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 86 | 137 | $30,825 | $10,784 | 35.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 84 | 84 | $33,600 | $10,351 | 30.8% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2022 | 61 | 62 | $36,208 | $9,603 | 26.5% |
| 95813 | Measurement of brain wave activity (eeg), 61-119 minutes | Office | 2022 | 14 | 14 | $13,944 | $4,570 | 32.8% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2022 | 25 | 25 | $12,225 | $3,393 | 27.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 11 | 11 | $2,893 | $970.25 | 33.5% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2022 | 12 | 12 | $1,686 | $538.44 | 31.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 249 | 346 | $61,588 | $21,408 | 34.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 142 | 177 | $46,551 | $16,046 | 34.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 96 | 96 | $38,400 | $11,792 | 30.7% |
| 95911 | Nerve transmission studies, 9-10 studies | Office | 2021 | 67 | 69 | $40,296 | $11,577 | 28.7% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2021 | 90 | 135 | $30,375 | $10,703 | 35.2% |
| 95813 | Measurement of brain wave activity (eeg) extended monitoring, 61-119 minutes | Office | 2021 | 27 | 27 | $26,892 | $8,415 | 31.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 38 | 38 | $19,000 | $5,939 | 31.3% |
About Dr. Taseer Minhas, MD
Dr. Taseer Minhas, MD is a Neurology healthcare provider based in Vestal, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508941972.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Taseer Minhas, MD has received a total of $16,431 in payments from pharmaceutical and medical device companies, with $2,611 received in 2024. These payments were reported across 923 transactions from 62 companies. The most common payment nature is "Food and Beverage" ($16,160).
As a Medicare-enrolled provider, Minhas has provided services to 2,791 Medicare beneficiaries, totaling 3,473 services with total Medicare billing of $311,924. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Vestal, NY
- Active Since 10/26/2006
- Last Updated 02/21/2020
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1508941972
Products in Payments
- UBRELVY (Drug) $3,320
- QULIPTA (Drug) $1,055
- Briviact (Drug) $591.93
- AUSTEDO (Drug) $416.90
- TROKENDI XR (Drug) $372.18
- APTIOM (Drug) $365.56
- BOTOX (Biological) $363.48
- NURTEC ODT (Drug) $337.79
- KESIMPTA (Drug) $325.00
- AJOVY (Biological) $302.84
- AUBAGIO (Drug) $295.30
- Aimovig (Biological) $282.50
- ZEPOSIA (Drug) $272.17
- COPAXONE (Drug) $253.05
- Rebif (Biological) $251.18
- APOKYN (Drug) $235.57
- TYSABRI (Biological) $231.04
- MAYZENT (Drug) $214.60
- RYTARY (Drug) $203.11
- AIMOVIG (Biological) $169.08
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.